Arzneimittelforschung 2002; 52(7): 560-564
DOI: 10.1055/s-0031-1299930
Antidiabetics
Editio Cantor Verlag Aulendorf (Germany)

HPLC Method for the Determination of Rosiglitazone in Human Plasma and its Application in a Clinical Pharmacokinetic Study

Rao N. V. S. Mamidi
a   Drug Metabolism and Pharmacokinetics Laboratory, Department of Preclinical Biology, Dr. Reddy’s Research Foundation, Hyderabad, India
,
Madhusudana R. Chaluvadi
a   Drug Metabolism and Pharmacokinetics Laboratory, Department of Preclinical Biology, Dr. Reddy’s Research Foundation, Hyderabad, India
,
Biju Benjamin
a   Drug Metabolism and Pharmacokinetics Laboratory, Department of Preclinical Biology, Dr. Reddy’s Research Foundation, Hyderabad, India
,
Mullangi Ramesh
a   Drug Metabolism and Pharmacokinetics Laboratory, Department of Preclinical Biology, Dr. Reddy’s Research Foundation, Hyderabad, India
,
Kasiram Katneni
a   Drug Metabolism and Pharmacokinetics Laboratory, Department of Preclinical Biology, Dr. Reddy’s Research Foundation, Hyderabad, India
,
Aravinda P. Babu
b   Corporate Medical Services, Dr. Reddy’s Laboratories Ltd., Hyderabad, India
,
Jaydip Bhanduri
b   Corporate Medical Services, Dr. Reddy’s Laboratories Ltd., Hyderabad, India
,
Naidu M. U. Rao
c   Clinical Pharmacology and Therapeutics, Nizam’s Institute of Medical Sciences, Hyderabad, India
,
Ramanujam Rajagopalan
a   Drug Metabolism and Pharmacokinetics Laboratory, Department of Preclinical Biology, Dr. Reddy’s Research Foundation, Hyderabad, India
› Author Affiliations
Further Information

Publication History

Publication Date:
26 December 2011 (online)

Summary

Rosiglitazone (CAS 155141-29-0, Avandia®) is a novel insulin sensitizer used in the treatment of type 2 diabetes. A sensitive high performance liquid chromatography (HPLC) method for its determination in human plasma using fluorescence detection (excitation: 247 nm, emission: 367 nm) with a suitable internal standard (I. S.) is described. Ethyl acetate was used as extraction solvent. A mobile phase consisting of phosphate buffer, acetonitrile and methanol was used at a flow rate of 1.0 ml/min on a C18 column. The absolute recovery was > 90 % and the lower limit of quantitation was 5 ng/ ml. The intra- and inter-day relative standard deviations ranged from 0.58-6.69 % and 0.82-6.63 %, respectively. The method described is simple, economical, precise and accurate and has been successfully applied in a pharmacokinetic study conducted in healthy human volunteers.

Zusammenfassung

HPLC-Methode zur Bestimmung von Rosiglitazon in Humanplasma und ihre Anwendung in einer klinisch-pharmakokinetischen Studie

Es wird eine empfindliche hochdruckflüssigchromatographische (HPLC)-Methode zur Bestimmung von Rosiglitazon (CAS 155141-29-0, Avandia®), einem neuen Wirkstoff zur Behandlung des Typ-II-Diabetes, in Humanplasma beschrieben. Die Messung erfolgte mit Hilfe eines Fluoreszenzdetektors (Anregung: 247 nm, Emission: 367 nm) mit einem Strukturanalogon als internem Standard. Als Extraktionsmittel diente Essigsäureethylester und als mobile Phase Phosphatpuffer, Acetonitril und Methanol bei einer Flußrate von 1,0 ml/min auf einer C18-Säule. Die absolute Wiederfindungsrate betrug < 90 %, die untere Erfassungsgrenze lag bei 5 ng/ml. Die Standardabweichungen in der Serie und von Tag zu Tag betrugen 0,58-6,69 % bzw. 0,82-6,63 %. Das einfache, kostengünstige und genaue Verfahren wurde in einer pharmakokinetischen Studie mit gesunden Freiwilligen erfolgreich eingesetzt.